Gain Therapeutics files $100M mixed securities shelf
17:02 EDT Gain Therapeutics (GANX) files $100M mixed securities shelf
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
24 minutes ago
- Business Insider
‘Nothing Lasts Forever,' Says Top Investor About Palantir Stock
Palantir (NASDAQ:PLTR) stock presents investors with quite a quandary. Confident Investing Starts Here: On the one hand, there is no denying that the company has delivered incredible growth over the past few years. Its revenues are skyrocketing, its margins are strong, and its list of customers continues to grow by leaps and bounds. Its share price has responded in kind, surging by over 466% over the past twelve months. And therein lies the rub, as PLTR is now trading at elevated multiples that are far and above the sector average. This leads to the question of whether all that company growth has led to enthusiasm that is a bit too optimistic. Top investor Riyado Sofian is decidedly on the fence, and is not sure which way the winds will blow. 'It's hard to decide whether to buy or sell — best to just hold it,' states the 5-star investor, who is in the top 3% of TipRanks' stock pros. Sofian outlines the bull case, describing a company that has introduced game-changing AI technology that sets the firm apart from its peers. Beyond the growing sales, profits, and customers, the investor also points out that revenues from Palantir's top 20 customers increased by 26% year-over-year, a strong indication of customer satisfaction. While the company continues to raise its guidance, it often succeeds in going well beyond these numbers, notes Sofian, and it has repeatedly 'destroyed its guidance' in previous quarters. In other words, more massive growth could be on the horizon for Palantir. 'All things considered, this is execution on an elite level — there's no denying it,' adds Sofian. And yet, judging by traditional metrics, the company is overvalued, the investor acknowledges, and its narrative as 'the most important AI company in the West' is what has powered its continuing ascent. For that reason, as long as the company's growth continues apace, PLTR should continue to rise as well. However, that is far from certain, and at a valuation of 100x its revenues, there is practically no room for error if the impressive rate starts to slow. To this point, Sofian reminds investors that nothing lasts forever. With neither a Buy nor a Sell looking particularly appealing, Sofian is splitting the difference and rating PLTR shares a Hold (i.e. Neutral). (To watch Sofian's track record, click here) That stance is echoed across Wall Street. Of the 18 analyst reviews on file, 11 say Hold, while just 3 recommend Buy and 4 suggest Sell, making PLTR a consensus Hold. The average 12-month price target sits at $101.06, implying a ~23% downside from current levels. (See PLTR stock forecast) To find good ideas for AI stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Business Insider
an hour ago
- Business Insider
Leader Capital Markets Reaffirms Their Buy Rating on Teva (TEVA)
Leader Capital Markets analyst Sabina Levi maintained a Buy rating on Teva (TEVA – Research Report) today and set a price target of ILA9,300.00. The company's shares closed yesterday at ILA6,281.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Levi is an analyst with an average return of -5.5% and a 0.00% success rate. The analyst consensus on Teva is currently a Hold rating. Based on Teva's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of ILA3.89 billion and a net profit of ILA214 million. In comparison, last year the company earned a revenue of ILA3.82 billion and had a GAAP net loss of ILA139 million
Business Insider
an hour ago
- Business Insider
Stock Futures Inch Up as Markets Eye U.S.-China Trade Developments
U.S. stock futures edged up slightly on Monday night as investors looked ahead to fresh updates on U.S.-China trade talks. Futures on the Nasdaq 100 (NDX), the Dow Jones Industrial Average (DJIA), and the S&P 500 (SPX) were up 0.06%, 0.02%, and 0.05%, respectively, at 8:23 p.m. EST, June 9. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The modest movement followed a quiet day on Wall Street, as investors focused on ongoing trade talks between the U.S. and China, including rare earth exports and the potential easing of U.S. tech restrictions. The discussions are set to resume Tuesday morning. During Monday's regular trading session, the S&P 500 rose nearly 0.1%, marking its second straight day of gains. The Dow closed just below the flatline, while the Nasdaq Composite (NDAQ) inched up by about 0.3%.
